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Fabry disease - importance of screening in cornea verticillata: case report
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INTRODUCTION
Fabry disease (FD) is an X-linked disease caused by deficient activity
of lysosomal enzyme α-galactosidase A (α-Gal A). Glycosphingolipids
(GL) accumulate in the lysosomes of various cells (eg, in the vascular
endothelium of multiple organs) owing to α-Gal A deficiency. The
accumulation of GL in the lysosomes causes cellular dysfunction;
this, in turn, triggers cells cascade and tissue ischemia and fibrosis.
The incidence of Fabry disease is estimated to be approximately
1:50,000 males(1).
The first clinical manifestations of the disease, which consist of
episodes of severe pain in the extremities (acroparesthesias), corneal
changes and skin lesions (angiokeratoma) develop in the childhood
or early adolescence. In the third and fourth decades, the progres-
sive deposition of GL in blood vessels and smooth muscles leads to
cardiovascular changes like angina pectoris and congestive heart
failure. Other features like a renal failure, stroke and hypoacusis may
also occur(2,3). Elderly heterozygotes female carriers occasionally de-
velop related symptoms similar to male patients(4).
Cornea verticillata is the most frequent ocular finding of Fabry
disease. Women are carriers and, in most cases, a vortex keratopathy
pattern is found. Visual impairment is an uncommon finding. Lens
opacities may occur with granular deposits in posterior capsule. Aneu-
rysmal dilatation and tortuosity of conjunctival and retinal vessels may
also occur(5,6).
Treatment is composed of medications to alleviate symptoms
as also disease-specific therapy to delay and prevent possible serious
organ damage. Enzyme reposition therapy (ERT) provides the bio-
logically functional protein to the patient. The goals of therapy are
improvement of symptoms and prevention of disease complica-
tions. Multiple clinical trials with recombinant α-Gal A have been
performed to investigate the safety and efficacy of ERT in patients
RESUMO
A doença de Fabry é um erro inato no metabolismo de glicosfingolipides (GL) ligado ao
cromossomo X. O acúmulo de GL nos tecidos pode afetar múltiplos órgãos e sistemas. Os
sintomas iniciais incluem episódios de dor nas extremidades, córnea verticilata e lesões na
pele. Em estágios avançados, os rins, coração e cérebro podem ser envolvidos. Este relato de
caso enfatiza para importância da córnea verticilata para o diagnóstico de doença de
Fabry em paciente jovem com dor nos membros inferiores.
Descritores: Doença de Fabry/diagnóstico; Opacidade da córnea; Relato de caso
ABSTRACT
Fabry disease is an X-linked disease of glycosphingolipid (GL) metabolism. The accu-
mulation of GL in tissues can affect multiple organ systems. Initial symptoms includes
episodes of severe pain in the extremities, cornea verticillata and skin lesions. In late
stages, kidney, heart and brain can be involved. This report attempts for importance
of cornea verticillata in the diagnosis of Fabry disease in a young patient with pain in
the lower limb extremities.
Keywords: Fabry disease/diagnosis; Corneal opacity; Case report
with Fabry disease. The rate of progression of renal, cardiac, and ce-
rebrovascular complications and death among patients who re-
ceived active drug was reduced compared with the placebo group.
Current recommendations suggest that ERT should be initiated as
early as possible in all males with Fabry disease(4,6).
CASE REPORT
A 16 year-old boy was referred to the Department of Ophthal-
mology of the Universidade Federal de São Paulo - UNIFESP during
investigation of Marfan Syndrome. He was under evaluation com-
plaining of pain and paresthesia in both feet for six months. He had
been previously evaluated by a pediatrician and performed a rheuma-
tologic screening with negative results. He had no ophthalmolo-
gical complaints and his past medical and ocular history were unre-
markable. He also had no familial history of genetic disorders or
ocular diseases.
The ophthalmological exam revealed uncorrected visual acuity
of 20/20 in both eyes and slit-lamp evaluation disclosed bilateral
cornea verticillata (Figure 1). Careful examination of anterior and
posterior segments did not show any other finding with no signs to
support the diagnosis of Marfan Syndrome based on the ophthal-
mological evaluation.
He never used any medication that could cause corneal depo-
sits, such as amiodarone, chloroquine, indomethacin, and pheno-
thiazines.
A comprehensive physical examination was performed revealing
angiokeratomas around the navel and petechiae in his back and arms.
Fabry disease was suspected and the patient was referred for
genetic evaluation. The low activity of α-Gal A associated with clinical
manifestation confirmed the diagnosis.
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The family was invited for ophthalmic evaluation. The father had
a normal ocular exam, but the examination of the mother revealed
vortex keratopathy (carrier) and his brother had cornea verticillata
and angiokeratomas with no other signs or symptoms of the di-
sease (Figure 2).
DISCUSSION
In this case, the disclosure of cornea verticillata was decisive for
the diagnosis of Fabry disease, and led to the diagnosis of his brother
and his mother. In the Fabry Outcome Survey registry, cornea ver-
ticillata was present in 77% of females and 73% of males under-
going detailed ophthalmic examination(3). Slit-lamp examination
reveals cornea verticillata, which manifests as whirl-like white-to-
golden-brown opacities that extend from the center to the peri-
phery of the cornea. Vision is not usually impaired. Cornea verti-
cillata is often prominent in female carriers and play an important
role in the early recognition of Fabry disease.
Lenticular changes are present in approximately 30% of affected
males and include a characteristic pattern of granular anterior capsular
or subcapsular deposit (Fabry cataract). The cataracts, which are best
observed through a dilated pupil slit-lamp examination using retroil-
lumination are whitish, with spoke-like deposits of fine granular mate-
rial on or near the posterior lens capsule. These lines usually radiate
from the central part of the posterior cortex(3). Aneurysmal dilatation
and tortuosity of conjunctival and retinal vessels may also occur. Data
from Fabry Outcome Survey indicate that vessel tortuosity is observed
more frequently in individuals with a higher disease severity score(3).
When the familial history is unknown, the diagnosis becomes
difficult and frequently delayed, leading to retardation of enzyme
replacement therapy and an increased morbidity due to cardiac,
renal and brain complications. Some patients die from stroke, heart
attack and congestive heart failure secondary to aneurismal chan-
ges caused by Fabry disease without diagnosis(7,8).
The α-Gal A activity may be measured in plasma, serum, leuko-
cytes, tissue biopsies and cultured skin fibroblasts. In males, the
most efficient and reliable method for the diagnosis of Fabry disease
is the demonstration of deficient α-Gal A enzyme activity in plasma,
isolated leukocytes, and/or cultured cells. In females, measurement
of α-Gal A enzyme activity is unreliable. Many female carriers have
normal α-Gal A enzyme activity, although, demonstration of de-
creased α-Gal A enzyme activity is diagnostic of the carrier state.
The screening for female carriers can be done with the ophthalmic
examination based on the presence of cornea verticillata present in
70-90% of females carrier(5,9).
CONCLUSION
Cornea verticillata is a relatively common ocular finding, typi-
cally presenting with no associated visual impairment. However,
young patients should be investigated for possible genetic disor-
ders especially when there is no history of use of medications related
with corneal deposits. With early diagnosis of Fabry disease, enzyme
replacement therapy can be instituted, avoiding serious compli-
cations and decreasing the morbidity and mortality associated with
the disease.
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Figure 1. Index case. 16 year-old male. A and B) Cornea verticillata; C) Angiokeratomas;





Figure 2. A-B) Brother. 11 y-o, assymptomatic, cornea verticillata, angiokeratomas; C-D)
Mother, 36 y-o, assymptomatic carrier with cornea verticilatta.
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